SG Americas Securities
ELDN icon

SG Americas Securities’s Eledon Pharmaceuticals ELDN Stock Holding History

SG Americas Securities’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-635,845
Closed -$1.96M – 3433
2026
Q1 		$1.96M Buy
635,845
+8,453
+1% +$19.9K ﹤0.01% 1408
2025
Q4 		$947K Buy
+627,392
New +$1.49M ﹤0.01% 2066
2025
Q2 		– Sell
-15,089
Closed -$51K – 3123
2025
Q1 		$51K Buy
+15,089
New +$62.1K ﹤0.01% 3239
2017
Q2 		– Sell
-407
Closed -$55K – 3258
2017
Q1 		$55K Buy
+407
New +$59.8K ﹤0.01% 3100
2016
Q4 		– Sell
-145
Closed -$36K – 3191
2016
Q3 		$36K Buy
+145
New +$53.1K ﹤0.01% 3209

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

SG Americas Securities's ELDN Position: Q2 2026 in Review

SG Americas Securities sold out of Eledon Pharmaceuticals (ELDN) in Q2 2026, closing a stake of 635,845 shares — an estimated $1.96M sold.

SG Americas Securities first reported a position in ELDN in Q3 2016 and held it in 5 quarters. The position peaked at $1.96M in Q1 2026. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • SG Americas Securities reported no remaining Eledon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 635,845 Eledon Pharmaceuticals shares in Q2 2026, an estimated $1.96M.
  • SG Americas Securities first reported a position in Eledon Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • SG Americas Securities's Eledon Pharmaceuticals position peaked at $1.96M in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.